Drug Information

Drug (ID: DG01804) and It's Reported Resistant Information

• Name: Catalpol
• Synonyms: Catalpol; 2415-24-9; Catalpinoside; CHEMBL513223; CHEBI:69797; De(p-hydroxybenzoyl)catalposide; UNII-JCX5L7JIC2; JCX5L7JIC2; Catalposide, des-p-hydroxybenzoyl-; EINECS 219-324-0; Digitalis purpurea L; SCHEMBL420515; Catalpol, >=96% (HPLC); DTXSID60178850; HY-N0820; ZINC8234298; BDBM50259972; AKOS024264429; AC-8052; AM84820; CCG-208299; LMPR0102070007; NCGC00163523-01; (1AS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl-beta-D-glucopyranoside; AS-75213; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy- 1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1a-alpha,1b-beta,2-beta,5a-beta,6-beta,6a-alpha))-; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-; N1352; SR-05000002315; Q1050267; SR-05000002315-2; (1aS,1bS,2S,5aR,6S,6aS)-1a,1b,2,5a,6,6a-Hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2-yl beta-D-glucopyranoside; (1S,5R,6R)-2-[(1S,1bS,2S,5aR,6S)-6-hydroxy-1a-((S)-hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydro-1,3-dioxa-cyclopropa[a]inden-2-yloxy]-6-((S)-hydroxymethyl)-tetrahydro-pyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-(((1aS,1bS,2S,5aR,6S,6aS)-6-hydroxy-1a-(hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydrooxireno[2',3':4,5]cyclopenta[1,2-c]pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[[(1S,2S,4S,5S,6R,10S)-5-hydroxy-2-(hydroxymethyl)-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-10-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-{[(1S,2S,4S,5S,6R,10S)-5-HYDROXY-2-(HYDROXYMETHYL)-3,9-DIOXATRICYCLO[4.4.0.0(2), ]DEC-7-EN-10-YL]OXY}-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Diabetic cardiomyopathy [ICD-11: BC43]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Myocardial injury [ICD-11: NB31]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 4
• IsoSMILES: C1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]3[C@@]2(O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
• InChI: InChI=1S/C15H22O10/c16-3-6-9(19)10(20)11(21)14(23-6)24-13-7-5(1-2-22-13)8(18)12-15(7,4-17)25-12/h1-2,5-14,16-21H,3-4H2/t5-,6-,7-,8+,9-,10+,11-,12+,13+,14+,15-/m1/s1
• InChIKey: LHDWRKICQLTVDL-PZYDOOQISA-N
• PubChem CID: 91520

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-11: Circulatory system diseases

Diabetic cardiomyopathy [ICD-11: BC43]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Diabetic cardiomyopathy [ICD-11: BC43.7]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Mouse cardiomyocytes; Heart; Mus musculus (Mouse); CVCL_JK52
• In Vivo Model: Diabetes male C57BL/6 mice model; Mus musculus
• Experiment for Molecule Alteration: Luciferase assay; Overexpression assay; Knockdown assay
• Experiment for Drug Resistance: TUNEL assay
• Mechanism Description: Catalpol alleviated myocardial damage by regulating Neat1/miR-140-5p/HDAC4 axis in DCM mice.

ICD-22: Injury/poisoning/certain external causes consequences

Myocardial injury [ICD-11: NB31]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Myocardial injury [ICD-11: NB31.Z]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Mouse harvested primary cardiomyocytes; N.A.; Mus musculus (Mouse); N.A.
• Experiment for Molecule Alteration: Luciferase assay; ChIP assay
• Experiment for Drug Resistance: TUNEL assay; Cellular ROS detection assay
• Mechanism Description: Inhibition of LncRNA Neat1 by catalpol via suppressing transcriptional activity of NF-kappa-B attenuates cardiomyocyte apoptosis.

References

• Ref 1: Catalpol attenuates cardiomyocyte apoptosis in diabetic cardiomyopathy via Neat1/miR-140-5p/HDAC4 axisBiochimie. 2019 Oct;165:90-99. doi: 10.1016/j.biochi.2019.05.005. Epub 2019 May 9.